Tango Therapeutics, Inc. TNGX
25.73 USD +1.43 (+5.88%)
At closeNov 11, 2026, 7:43 PM EST
25.73 0.00 0.00%
After hours · Nov 11, 7:43 PM ET
23.87 Day range 26.41
7.67 52-week range 32.90
- YTD
- +190.41%
- 1 year
- +207.04%
News
defenseworld.net Tango Therapeutics (NASDAQ:TNGX) Stock Price Breaks Above 50-Day Moving Average After Earnings Miss Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Tuesday after the company announced better than expected quarterly…
benzinga.com JP Morgan Maintains Overweight on Tango Therapeutics, Raises Price Target to $47 JP Morgan analyst Brian Cheng maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and raises the price target from $46 to $47.
benzinga.com Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $40 Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target from $45 to $40.
benzinga.com HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Lowers Price Target to $67 HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price target from $68 to $67.
benzinga.com Tango Therapeutics Q3 EPS $(0.39) Misses $(0.35) Estimate Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.35) by 11.43 percent. This is a 378.57 percent decrease over…
globenewswire.com Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progression-free…
globenewswire.com Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 BOSTON and SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that…
globenewswire.com Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) today announced that Malte Peters, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to…
seekingalpha.com Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity Tango Therapeutics upgraded from 'Hold' to 'Buy' following strong phase 1/2 data for vopimetostat + RASONQUE in MTAP-del, 2nd-line/3rd-line RAS-mutant PDAC. Company's combination therapy showed an…- benzinga.com HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $68 price target.
seekingalpha.com Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer, outperforming historical controls. I view the ESMO-driven sell-off as overdone, given TNGX's…
zacks.com TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
seekingalpha.com Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript
benzinga.com Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings U.S. stocks fell Friday: Dow -1.12%, S&P 500 -0.43%, Nasdaq -0.13%. Energy and oil rose; SLB gained 7% on strong results.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
marketbeat.com Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate Tango Therapeutics NASDAQ: TNGX said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for…
benzinga.com Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? Tango Therapeutics Inc. (NASDAQ:TNGX) on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing strong efficacy in treating advanced pancreatic and lung cancers.
benzinga.com Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? Tango Therapeutics reports an 82% response rate in pancreatic cancer trials and prepares a randomized registrational study for early 2027.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…- benzinga.com Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, today…
investors.com Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.
globenewswire.com Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy 82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib
benzinga.com Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday U.S. stocks were mixed as the Dow gained 400 points. Winnebago jumped 7% on an EPS beat, while Super Micro and SpaceX rallied on strong outlooks.- benzinga.com William Blair Initiates Coverage On Tango Therapeutics with Outperform Rating William Blair analyst Alethia Young initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Outperform rating.
- benzinga.com Tango Therapeutics To Present Updated Data From Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib Or Zoldonrasib In Patients With MTAPdel/RASmut Metastatic PDAC And NSCLC At ESMO Congress 2026 Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the…
globenewswire.com Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET
defenseworld.net Tango Therapeutics (NASDAQ:TNGX) vs. Alumis (NASDAQ:ALMS) Financial Analysis Tango Therapeutics (NASDAQ: TNGX - Get Free Report) and Alumis (NASDAQ: ALMS - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses…
defenseworld.net Alnylam Pharmaceuticals (NASDAQ:ALNY) & Tango Therapeutics (NASDAQ:TNGX) Head to Head Survey Alnylam Pharmaceuticals (NASDAQ: ALNY - Get Free Report) and Tango Therapeutics (NASDAQ: TNGX - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the…
defenseworld.net Tidal Investments LLC Purchases Shares of 55,384 Tango Therapeutics, Inc. $TNGX Tidal Investments LLC acquired a new stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional…
zacks.com Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?
benzinga.com Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.
globenewswire.com Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of…
globenewswire.com Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to…
defenseworld.net Algert Global LLC Grows Position in Tango Therapeutics, Inc. $TNGX Algert Global LLC boosted its holdings in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) by 86.5% during the second quarter, according to the company in its most recent disclosure with the…
benzinga.com HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68 HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $66 to $68.
benzinga.com Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35 Guggenheim analyst Michael Schmidt maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $32 to $35.- benzinga.com Tango Therapeutics Files Prospectus For Up To $400M Common Stock Offering Up to $400,000,000Common StockWe have previously entered into a Sales Agreement, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, dated November 21, 2025, relating to the sale…
benzinga.com Tango Therapeutics Q2 EPS $(0.37) Misses $(0.32) Estimate Tango Therapeutics (NASDAQ:TNGX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.32) by 15.62 percent. This is a 5.71 percent decrease over losses of…- benzinga.com Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40 Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $36 to $40.
benzinga.com This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings and price targets.
benzinga.com JP Morgan Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $46 JP Morgan analyst Brian Cheng initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating and announces Price Target of $46.- benzinga.com Canaccord Genuity Maintains Buy on Tango Therapeutics, Raises Price Target to $46 Canaccord Genuity analyst John Newman maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $42 to $46.
- benzinga.com Jefferies Upgrades Tango Therapeutics to Buy, Raises Price Target to $60 Jefferies analyst Maury Raycroft upgrades Tango Therapeutics (NASDAQ:TNGX) from Hold to Buy and raises the price target from $27 to $60.
- benzinga.com HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $66 HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and raises the price target from $27 to $66.
benzinga.com Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are On Investors' Radars Today AAPL, SUNE, TNGX, APLD, CBRS were among the stocks seen trending on Monday, June 8, 2026.- benzinga.com Tango Therapeutics Launches $500M Common Stock Offering Tango Therapeutics, Inc. ("Tango") (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings US stocks rose with Nasdaq up 400 points. Dow up 0.32%, Nasdaq up 1.55%, S&P 500 up 0.94%. Tech shares rose, communication services fell. Motorcar Parts of America stock jumped 37% on strong…
benzinga.com Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers include ENHA, JLHL, ABAT, BTGO, GLXY, CLYM, SOC, SRAD, AIAI, ALOY, and…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session